Can’t hack it? Bellus tolls for GSK phase III cough drug
· randy osborne
AI Briefing
- • GSK abandons camlipixant due to phase III cough drug trial results.
- • Trevi Therapeutics' Haduvio shows positive phase II data in treating chronic cough.
- • Trevi shares rise 9.9% to $19.07 after positive phase II results announcement.
Source Summary
GSK plc’s walk-away from refractory chronic cough prospect camlipixant because of dicey phase III results opened the door wider for Trevi Therapeutics Inc. with Haduvio (oral nalbuphine ER), which yielded positive phase II data in June. Shares of Trevi (NASDAQ:TRVI) closed July 17 at $19.07, up $1.71, or 9.9%.
Advertisement